Biotech Values

[rkrw]

<<It seems that patients just don’t like getting poked in the eye every month, especially when some of the pokes result in serious inflammation.>>

Could this be a good reason why qlti may better compete against macugen than expected? And perhaps visudyne is the real competition for squalamine? Is the data for eyet that much more compelling than qlt?

An example of ease of delivery advantages is in PAH. Gold standard efficacy comes from very invasive drugs (flolan) yet highest market share is from a BID pill (tracleer).